Karl-Ernst Siegler

USPTO Granted Patents = 8 (Patent Applications = 2)

Average Co-Inventor Count = 6.7

ph-index = 1

Company Filing History:

7 out of 1,827

Sanofi-a Ventis Deutschland Gmbh

Years Active: 2007-2013

Loading Chart...

8 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 8420321 - Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism (2013-04-16),

2. 8198022 - Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof (2012-06-12),

3. 8084198 - Use of a GIP promoter polymorphism (2011-12-27),

4. 7985562 - Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-lle347 polymorphism (2011-07-26),

5. 7892744 - Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders (2011-02-22),

6. 7888020 - Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof (2011-02-15),

7. 7560290 - Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism (2009-07-14),

8. 7262273 - Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof (2007-08-28),

Title: The Innovations of Karl-Ernst Siegler

Introduction

Karl-Ernst Siegler is a notable inventor based in Ludwigshafen, Germany. He has made significant contributions to the field of medical science, particularly in identifying risks associated with thrombogenic disorders and diabetes. With a total of eight patents to his name, Siegler's work has the potential to impact patient care and treatment options.

Latest Patents

One of Siegler's latest patents is a method for identifying a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism. This invention aims to identify risks for conditions such as atrial fibrillation, stroke, and coronary heart disease. Another significant patent involves the association of the EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis. This method helps in identifying an increased risk for these conditions based on specific amino acid exchanges in the EDG5 protein.

Career Highlights

Siegler has worked with prominent companies in the pharmaceutical industry, including Sanofi-Aventis Deutschland GmbH and Sanofi-Aventis. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical diagnostics and treatment.

Collaborations

Throughout his career, Siegler has collaborated with notable professionals in his field, including Detlef Kozian and Jean-Francois Deleuze. These collaborations have likely enriched his research and contributed to the success of his inventions.

Conclusion

Karl-Ernst Siegler's contributions to medical science through his patents demonstrate his commitment to improving patient outcomes. His innovative methods for identifying risks associated with thrombogenic disorders and diabetes highlight the importance of research and development in healthcare.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

2 patents pending:

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.